These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 15816507)

  • 1. Novel antithrombotic strategies in cardiovascular diseases.
    Golino P; Loffredo F; Riegler L; Renzullo E; Cocchia R
    Curr Opin Investig Drugs; 2005 Mar; 6(3):298-306. PubMed ID: 15816507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cardiovascular events after acute coronary syndrome.
    Wallentin L
    Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulation.
    Turpie AG; Esmon C
    Thromb Haemost; 2011 Apr; 105(4):586-96. PubMed ID: 21225099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.
    Lee YK; Player MR
    Med Res Rev; 2011 Mar; 31(2):202-83. PubMed ID: 19967784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties.
    Stassen JM; Lambeir AM; Matthyssens G; Ripka WC; Nyström A; Sixma JJ; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):646-54. PubMed ID: 8585001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New anticoagulants].
    Levi M; Peters RJ; Piek JJ; Büller HR
    Ned Tijdschr Geneeskd; 2003 May; 147(19):909-15. PubMed ID: 12768805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 11. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin as a common downstream target blocking both platelet and monocyte activation.
    Santilli F; Davì G
    Thromb Haemost; 2009 Feb; 101(2):220-1. PubMed ID: 19190800
    [No Abstract]   [Full Text] [Related]  

  • 15. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
    Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
    Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents.
    Angiolillo DJ; Ferreiro JL
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):233-50. PubMed ID: 23613159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombosis and its therapeutic targets].
    Drouet L
    Rev Prat; 1999 Oct; 49(15):1617-23. PubMed ID: 10581991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats.
    Hérault JP; Perrin B; Jongbloet C; Pflieger AM; Bernat A; Herbert JM
    Thromb Haemost; 2000 Oct; 84(4):668-74. PubMed ID: 11057868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antithrombotic drugs.
    Gross PL; Weitz JI
    Clin Pharmacol Ther; 2009 Aug; 86(2):139-46. PubMed ID: 19553932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.